Genmab and Argenx Join Forces to Unleash Revolutionary Therapies for Immunology and Oncology

Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) have joined forces to revolutionize the way we treat immunological and oncological diseases. Through this multiyear collaboration, the two companies will leverage their respective antibody engineering capabilities and knowledge of disease biology to discover and develop novel therapeutic antibodies. Their goal is to bring innovative medicines to patients, addressing the unmet needs in immunology and cancer.

Genmab is taking a bold step towards its vision of transforming the lives of people with cancer and other serious diseases by 2030 with its “KYSO” antibody medicines. As part of this, Genmab is now entering the field of immunology and inflammation.

By partnering with argenx, Genmab is able to combine its expertise in biology and therapeutic potential of antibodies to address the needs of patients in both oncology and immunology and inflammation. Jan van de Winkel, Ph.D., Chief Executive Officer at Genmab, said that this partnership is an exciting opportunity for Genmab to make its vision a reality.

At argenx, our core mission is to revolutionize healthcare by combining immunology breakthroughs with innovative pipeline candidates. Through our model of co-creation, we have achieved eight molecules demonstrating human proof-of-concept in our pipeline.

Now, by partnering with Genmab, we are leveraging both of our antibody discovery, development, and commercialization expertise to unlock the disease pathways for autoimmunity and cancer, allowing us to create more novel therapeutic antibodies than ever before.

Collaboration Details

Argenx and Genmab have joined forces to create a powerful partnership in the search for innovative antibody-based treatments in the field of immunology and cancer. The two companies will collaborate to discover, develop, and commercialize products coming from this collaboration, and will share both costs and profits equally.

By leveraging their respective suites of proprietary antibody technologies, argenx and Genmab aim to identify and develop lead antibody candidates for the treatment of differentiated diseases. This exciting partnership could potentially expand in the future to include even more targets.

About Genmab

Genmab is a biotechnology powerhouse with a clear mission: To improve the lives of patients with innovative and differentiated antibody therapeutics.

For more than two decades, its passionate and collaborative team has created revolutionary technology platforms and conducted groundbreaking research, resulting in a proprietary pipeline packed with the latest bispecific T-cell engagers, immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab has teamed up with biotechnology and pharmaceutical companies to bring these novel antibody therapies to the masses and by 2030, it aims to revolutionize the way we treat cancer and other serious diseases with KYSO antibody medicines.

About argenx

At argenx, we’re on a mission to revolutionize the treatment of severe autoimmune diseases by pioneering innovative immunology breakthroughs. We’re driven to create a world-class portfolio of novel antibody-based medicines, and have already achieved major success with the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU.

Currently, we are conducting clinical trials on efgartigimod in multiple serious autoimmune diseases and actively exploring a range of experimental medicines within our therapeutic franchises. We believe that together, we can make a real difference in the lives of those who suffer from these debilitating diseases.

Leave a Comment